These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27654896)

  • 1. Blocking peptides and molecular mimicry as treatment for kidney disease.
    Havasi A; Lu W; Cohen HT; Beck L; Wang Z; Igwebuike C; Borkan SC
    Am J Physiol Renal Physiol; 2017 Jun; 312(6):F1016-F1025. PubMed ID: 27654896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy in renal diseases.
    De Rechter S; Decuypere JP; Ivanova E; van den Heuvel LP; De Smedt H; Levtchenko E; Mekahli D
    Pediatr Nephrol; 2016 May; 31(5):737-52. PubMed ID: 26141928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting podocyte-associated diseases.
    Leeuwis JW; Nguyen TQ; Dendooven A; Kok RJ; Goldschmeding R
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1325-36. PubMed ID: 20828590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of podocyte-associated molecules in acquired human kidney diseases.
    Koop K; Eikmans M; Baelde HJ; Kawachi H; De Heer E; Paul LC; Bruijn JA
    J Am Soc Nephrol; 2003 Aug; 14(8):2063-71. PubMed ID: 12874460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protective effect of sirtuin 1.
    Dong YJ; Liu N; Xiao Z; Sun T; Wu SH; Sun WX; Xu ZG; Yuan H
    J Diabetes Res; 2014; 2014():843786. PubMed ID: 25386563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting signaling pathways in glomerular diseases.
    Henique C; Tharaux PL
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):417-27. PubMed ID: 22660552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and kidney disease.
    Ruiz-Ortega M; Ortiz A; Ramos AM
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):93-100. PubMed ID: 24257157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of cofilin in kidney disease].
    Li X; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Oct; 43(10):1159-1163. PubMed ID: 30523239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bibliography. Renal pathophysiology. Current world literature.
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):454-61. PubMed ID: 22826837
    [No Abstract]   [Full Text] [Related]  

  • 10. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease.
    Wang J; Masehi-Lano JJ; Chung EJ
    Biomater Sci; 2017 Jul; 5(8):1450-1459. PubMed ID: 28516997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy.
    Zoja C; Liu XH; Abbate M; Corna D; Schiffrin EL; Remuzzi G; Benigni A
    Exp Nephrol; 1998; 6(2):121-31. PubMed ID: 9567218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways.
    Liu Y; Rajur K; Tolbert E; Dworkin LD
    Kidney Int; 2000 Nov; 58(5):2028-43. PubMed ID: 11044223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirtuin and metabolic kidney disease.
    Wakino S; Hasegawa K; Itoh H
    Kidney Int; 2015 Oct; 88(4):691-8. PubMed ID: 26083654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G; Ritz E
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A slit in podocyte death.
    Moreno JA; Sanchez-Niño MD; Sanz AB; Lassila M; Holthofer H; Blanco-Colio LM; Egido J; Ruiz-Ortega M; Ortiz A
    Curr Med Chem; 2008; 15(16):1645-54. PubMed ID: 18673230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic agents in diabetic nephropathy.
    Kim Y; Park CW
    Korean J Intern Med; 2017 Jan; 32(1):11-25. PubMed ID: 28049280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Podocyte injury and targeting therapy: an update.
    Durvasula RV; Shankland SJ
    Curr Opin Nephrol Hypertens; 2006 Jan; 15(1):1-7. PubMed ID: 16340659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kidney Injury by Variants in the
    Frese J; Kettwig M; Zappel H; Hofer J; Gröne HJ; Nagel M; Sunder-Plassmann G; Kain R; Neuweiler J; Gross O
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Instructions and implementations for percutaneous renal biopsy. Guidelines for the therapy of glomerular nephropaties].
    Cagnoli L;
    G Ital Nefrol; 2003; 20 Suppl 24():S3-47. PubMed ID: 14666502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The insulin-like growth factor system in kidney disease and hypertension.
    Bach LA
    Curr Opin Nephrol Hypertens; 2012 Jan; 21(1):86-91. PubMed ID: 22123209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.